Try it
General Medicine · Infectious diseases: HIV and tuberculosis
Sample itemA man newly diagnosed with HIV, with a CD4 count of 30 cells/mm3, has smear-positive pulmonary tuberculosis and no neurological symptoms. He starts antituberculosis treatment. What is the best timing for starting antiretroviral therapy?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
B. Within 2 weeks of starting antituberculosis treatment
In HIV-associated tuberculosis, antituberculosis treatment is started first, and ART is begun within 2 weeks when the CD4 count is below 50, because delay raises mortality. In patients with higher CD4 counts ART can wait up to 8 weeks, and in tuberculous meningitis it is deferred to reduce serious adverse events. Dolutegravir dose is increased to twice daily with rifampicin, and IRIS should be anticipated.
Option by option
A. After 8 weeks of antituberculosis treatment
Delay to 8 weeks suits patients with higher CD4 counts, but is harmful at a CD4 of 30.
B. Within 2 weeks of starting antituberculosis treatment (correct)
Early ART within 2 weeks improves survival in severe immunosuppression.
C. After completing 6 months of antituberculosis treatment
Delaying until treatment completion exposes him to prolonged, severe immunodeficiency.
D. Only when the CD4 count rises above 200
Waiting for CD4 recovery is not possible without ART and is not recommended.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More General Medicine questions
- EndocrinologyA 19-year-old with type 1 diabetes presents with vomiting, deep rapid breathing, fruity…
- ElectrolytesWhich is the earliest ECG change in hyperkalaemia?
- Infectious diseaseWhat is the drug of choice for Pneumocystis jirovecii pneumonia in a patient with advanc…
- NeurologyA chronic alcohol user is brought in confused, with nystagmus and an unsteady gait. What…